ESSA Pharma Inc. (NASDAQ:EPIX – Get Free Report) (TSE:EPI) COO Peter Virsik sold 2,082 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.03, for a total transaction of $12,554.46. Following the completion of the transaction, the chief operating officer now owns 9,164 shares of the company’s stock, valued at approximately $55,258.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ESSA Pharma Stock Performance
Shares of ESSA Pharma stock opened at $5.93 on Wednesday. The business has a 50-day simple moving average of $5.12 and a 200-day simple moving average of $6.49. ESSA Pharma Inc. has a one year low of $2.58 and a one year high of $11.67. The company has a market cap of $263.07 million, a PE ratio of -9.41 and a beta of 1.82.
ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.10. On average, sell-side analysts predict that ESSA Pharma Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ESSA Pharma
Wall Street Analysts Forecast Growth
Separately, Oppenheimer reiterated an “outperform” rating and issued a $17.00 target price on shares of ESSA Pharma in a report on Thursday, May 16th.
Check Out Our Latest Report on EPIX
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
- Five stocks we like better than ESSA Pharma
- Investing in the High PE Growth Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- Want to Profit on the Downtrend? Downtrends, Explained.
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- What Investors Need to Know to Beat the Market
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.